Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)

A Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Trial to Assess the Efficacy and Safety of MK0663 in Patients With Chronic Low Back Pain

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00393354

Enrollment

325

Registered

2006-10-27

Start date

2000-04-30

Completion date

2000-11-30

Last updated

2022-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Low Back Pain

Brief summary

Study the effect of etoricoxib 60 mg and 90 mg compared to placebo to treat chronic low back pain.

Interventions

DRUGMK0663, Etoricoxib / Duration of Treatment : 12 Weeks

DRUGComparator : placebo (unspecified) /Duration of Treatment : 12 Weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Low back pain for previous 3 months and majority of days in last month * Regular use of acetaminophen or NSAID to treat low back pain in past month * Judged to be in otherwise good health

Exclusion criteria

* Low back pain that is due to secondary causes * Radicular/myelopathic pain * Surgery for low back pain within the past 6 months * Active lawsuit or claim pertaining to their low back pain * Disease that may confound the results of the study or pose risk to the patients * Corticosteroid use in past month * Previous participation in MK0663 study

Design outcomes

Primary

Measure	Time frame
Low back pain intensity scale (0-100 mm VAS) over 4 weeks compared to placebo	—

Secondary

Measure	Time frame
Low back pain intensity scale (0-100 mm VAS) over 12 weeks compared to placebo	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026